Market research

Multicancer Screening Market

Explore licensesfrom $3,939

Assess the study’s coverageRead the public overview, then compare the chapter outline with your research brief.

18report chapters

Public research overviewHow we research Research team

Multicancer Screening: Executive Overview

Multicancer screening refers to approaches designed to assess an individual for signals associated with more than one cancer type, commonly through a single test or coordinated screening pathway. The field brings together molecular diagnostics, imaging, clinical risk assessment, and follow-up care. Its value depends not only on analytical performance, but also on evidence of clinical benefit, appropriate patient selection, confirmatory diagnostics, and equitable access.

360iResearch introduction

Inside the research

Coverage at a glance

Selected branches from the published table of contents. Follow a chapter to see every subchapter in context.

  1. Chapter 7 Test Type

    • Gene Panel
    • Laboratory Developed Test
    • Liquid Biopsy
    View chapter
  2. Chapter 8 Cancer Type

    • Breast Cancer
    • Colorectal Cancer
    • Leukemia
    • Lung Cancer
    More in this chapter
  3. Chapter 9 Technology

    • Mass Spectrometry
    • Microarray
    • Next - Generation Sequencing
    • Polymerase Chain Reaction
    View chapter

From Single-Cancer Programs to Integrated Detection Pathways

The landscape is shifting from isolated, organ-specific screening programs toward risk-stratified pathways that combine personal history, inherited risk, symptoms, conventional screening, and emerging molecular signals. This transition creates a need for clear referral protocols, rapid diagnostic resolution, and safeguards against unnecessary procedures. Health systems must evaluate multicancer approaches alongside established screening programs rather than treating them as substitutes without supporting evidence.

Artificial Intelligence Strengthens Interpretation and Coordination

Artificial intelligence can support multicancer screening by identifying patterns in imaging, pathology, molecular data, and longitudinal clinical records. It may improve triage, prioritize confirmatory testing, and help integrate complex risk factors. However, reliable deployment requires representative validation data, transparent performance assessment, human oversight, cybersecurity, and monitoring for false positives, false negatives, and disparities across populations. AI should augment clinical judgment rather than replace diagnostic confirmation.

Regional Insights: Uneven Readiness Shapes Adoption

North America combines advanced diagnostic infrastructure with active evaluation of novel screening pathways, while Latin America faces variation in laboratory capacity, referral access, and public-sector resources. Europe is shaped by coordinated health systems, privacy requirements, and evidence standards, with implementation dependent on alignment with organized screening programs. The Middle East is investing in healthcare modernization but has differing levels of specialist capacity across countries. Africa’s priorities include affordability, decentralized testing, and linkage to care. Asia-Pacific spans highly sophisticated systems and resource-constrained settings, making adaptable delivery models and local validation particularly important.

Group Insights: Cooperation Can Accelerate Evidence and Access

ASEAN markets may benefit from shared technical standards, regional laboratory networks, and interoperable referral pathways. BRICS countries have substantial research, manufacturing, and healthcare diversity, but require approaches tailored to different public and private delivery environments. The European Union emphasizes cross-border data governance, clinical evidence, and coordinated health policy. G7 members generally possess strong research and diagnostic capabilities, while NATO members may also draw on resilient supply chains and preparedness infrastructure. GCC countries can leverage centralized health planning and modern clinical facilities, while continuing to address workforce development and population diversity.

Country Insights: Different Systems Require Different Implementation Models

Australia, Canada, France, Germany, Italy, Japan, South Korea, Spain, the United Kingdom, and the United States have established screening, research, or specialist-care infrastructure, but differ in reimbursement, regulatory pathways, data governance, and referral organization. China and India present large and diverse populations alongside varied regional access and healthcare capacity. Brazil, Mexico, and Russia also require implementation models that account for geographic scale, public-sector delivery, and uneven diagnostic availability. Across all countries, adoption should be guided by locally relevant evidence, culturally appropriate communication, and dependable pathways from a positive result to diagnostic resolution and treatment.

Action Priorities for Leaders: Prove Benefit Before Scaling

Industry leaders should prioritize prospective clinical evidence, clearly defined intended-use populations, and outcomes that measure diagnostic resolution, stage distribution, harms, and patient experience. They should design products with confirmatory testing and care navigation built in, engage regulators and payers early, and publish subgroup performance across age, sex, ethnicity, geography, and socioeconomic status. Partnerships with health systems can help establish interoperable workflows, while transparent communication should explain that a screening signal is not a diagnosis. Operational plans should also address laboratory quality, workforce training, data protection, and affordability.

Research Methodology: Evidence-Led, Geography-Aware Assessment

This executive summary uses a structured review of the multicancer screening domain, emphasizing publicly verifiable evidence from clinical studies, regulatory and policy materials, peer-reviewed research, screening guidelines, and health-system implementation literature. Findings are organized by technology, care pathway, artificial intelligence, geography, and stakeholder group. The assessment avoids unsupported quantitative claims and distinguishes established screening practice from emerging approaches. Regional, group, and country observations are framed as implementation considerations rather than predictions of adoption or commercial performance.

Conclusion: Clinical Utility and Equity Will Define Progress

Multicancer screening has the potential to complement existing cancer-control strategies by broadening risk assessment and coordinating detection across cancer types. Its long-term significance will depend on demonstrated clinical benefit, manageable downstream harms, accurate interpretation, and timely access to diagnostic and treatment services. Leaders who combine rigorous evidence generation with responsible AI, strong governance, and equitable delivery will be best positioned to translate technical innovation into meaningful public-health value.

Research report

Table of contents

  1. 1.Preface
    1. 1.1Objectives of the Study
    2. 1.2Market Definition
    3. 1.3Market Segmentation & Coverage
    4. 1.4Years Considered for the Study
    5. 1.5Currency Considered for the Study
    6. 1.6Language Considered for the Study
    7. 1.7Key Stakeholders
  2. 2.Research Methodology
    1. 2.1Introduction
    2. 2.2Research Design
      1. 2.2.1Primary Research
      2. 2.2.2Secondary Research
    3. 2.3Research Framework
      1. 2.3.1Qualitative Analysis
      2. 2.3.2Quantitative Analysis
    4. 2.4Market Size Estimation
      1. 2.4.1Top-Down Approach
      2. 2.4.2Bottom-Up Approach
    5. 2.5Data Triangulation
    6. 2.6Research Outcomes
    7. 2.7Research Assumptions
    8. 2.8Research Limitations
  3. 3.Executive Summary
    1. 3.1Introduction
    2. 3.2CXO Perspective
    3. 3.3New Revenue Opportunities
    4. 3.4Next-Generation Business Models
    5. 3.5Industry Roadmap
  4. 4.Market Overview
    1. 4.1Introduction
    2. 4.2Industry Ecosystem & Value Chain Analysis
      1. 4.2.1Supply-Side Analysis
      2. 4.2.2Demand-Side Analysis
      3. 4.2.3Stakeholder Analysis
    3. 4.3Market Dynamics
      1. 4.3.1Key Drivers
      2. 4.3.2Key Restraints
      3. 4.3.3Key Opportunities
      4. 4.3.4Key Challenges
    4. 4.4Porter’s Five Forces Analysis
    5. 4.5PESTLE Analysis
    6. 4.6Market Outlook
      1. 4.6.1Near-Term Market Outlook (0–2 Years)
      2. 4.6.2Medium-Term Market Outlook (3–5 Years)
      3. 4.6.3Long-Term Market Outlook (5–10 Years)
    7. 4.7Go-to-Market Strategy
  5. 5.Market Insights
    1. 5.1Consumer Insights & End-User Perspective
    2. 5.2Consumer Experience Benchmarking
    3. 5.3Opportunity Mapping
    4. 5.4Distribution Channel Analysis
    5. 5.5Pricing Trend Analysis
    6. 5.6Regulatory Compliance & Standards Framework
    7. 5.7ESG & Sustainability Analysis
    8. 5.8Disruption & Risk Scenarios
    9. 5.9Return on Investment & Cost-Benefit Analysis
  6. 6.Cumulative Impact of Artificial Intelligence 2026
  7. 7.Multicancer Screening Market, by Test Type
    1. 7.1Introduction
    2. 7.2Gene Panel
    3. 7.3Laboratory Developed Test
    4. 7.4Liquid Biopsy
  8. 8.Multicancer Screening Market, by Cancer Type
    1. 8.1Introduction
    2. 8.2Breast Cancer
    3. 8.3Colorectal Cancer
    4. 8.4Leukemia
    5. 8.5Lung Cancer
    6. 8.6Non-Specific Multi-Organ Cancer
    7. 8.7Prostate Cancer
  9. 9.Multicancer Screening Market, by Technology
    1. 9.1Introduction
    2. 9.2Mass Spectrometry
    3. 9.3Microarray
    4. 9.4Next - Generation Sequencing
    5. 9.5Polymerase Chain Reaction
  10. 10.Multicancer Screening Market, by Payment Source
    1. 10.1Introduction
    2. 10.2Government Subsidies
    3. 10.3Out-of-Pocket Payment
    4. 10.4Private Health Insurance
  11. 11.Multicancer Screening Market, by Application
    1. 11.1Introduction
    2. 11.2Diagnostic Screening
      1. 11.2.1Early Detection
      2. 11.2.2Risk Assessment
    3. 11.3Prognostics
      1. 11.3.1Patient Monitoring
      2. 11.3.2Therapy Selection
      3. 11.3.3Treatment Efficacy Assessment
    4. 11.4Research Applications
      1. 11.4.1Biomarker Discovery
      2. 11.4.2Genetic Research
  12. 12.Multicancer Screening Market, by End User
    1. 12.1Introduction
    2. 12.2Ambulatory Surgical Centers
    3. 12.3Diagnostic Centers
    4. 12.4Hospitals
    5. 12.5Research Institutions
    6. 12.6Specialty Clinics
  13. 13.Multicancer Screening Market, by Region
    1. 13.1Introduction
    2. 13.2Asia-Pacific
    3. 13.3Europe
    4. 13.4North America
    5. 13.5Latin America
    6. 13.6Africa
    7. 13.7Middle East
  14. 14.Multicancer Screening Market, by Group
    1. 14.1Introduction
    2. 14.2NATO
    3. 14.3G7
    4. 14.4BRICS
    5. 14.5European Union
    6. 14.6ASEAN
    7. 14.7GCC
  15. 15.Multicancer Screening Market, by Country
    1. 15.1Introduction
    2. 15.2China
    3. 15.3United States
    4. 15.4Japan
    5. 15.5India
    6. 15.6Germany
    7. 15.7United Kingdom
    8. 15.8Australia
    9. 15.9France
    10. 15.10South Korea
    11. 15.11Italy
    12. 15.12Canada
    13. 15.13Russia
    14. 15.14Brazil
    15. 15.15Mexico
    16. 15.16Spain
  16. 16.Competitive Landscape
    1. 16.1Market Share Analysis, 2025
    2. 16.2Market Concentration Analysis, 2025
      1. 16.2.1Concentration Ratio (CR)
      2. 16.2.2Herfindahl Hirschman Index (HHI)
    3. 16.3Recent Developments & Impact Analysis, 2025
    4. 16.4Product Portfolio Analysis, 2025
    5. 16.5Benchmarking Analysis, 2025
  17. 17.Company Profiles
    1. 17.1ANPAC Bio-Medical Science Co., Ltd.
    2. 17.2Burning Rock Biotech Limited
    3. 17.3Coyne Medical Ltd.
    4. 17.4Delfi Diagnostics, Inc.
    5. 17.5Elypta AB
    6. 17.6EpiCypher, Inc.
    7. 17.7Epigenomics AG
    8. 17.8Exact Sciences Corporation
    9. 17.9Foundation Medicine, Inc.
    10. 17.10Freenome Holdings, Inc.
    11. 17.11Fulgent Genetics, Inc.
    12. 17.12Gene Solutions
    13. 17.13Grail, LLC by Illumina, Inc.
    14. 17.14Guangzhou AnchorDx Medical Co., Ltd.
    15. 17.15Guardant Health, Inc.
    16. 17.16Invitae Corporation
    17. 17.17Laboratory Corporation of America Holdings
    18. 17.18Lucence Health Inc.
    19. 17.19Micronoma, Inc.
    20. 17.20MiRXES Pte Ltd.
    21. 17.21Myriad Genetics, Inc.
    22. 17.22Natera, Inc.
    23. 17.23Naveris, Inc.
    24. 17.24NeoGenomics Laboratories
    25. 17.25OneTest
    26. 17.26Siemens Healthineers AG
    27. 17.27StageZero Life Sciences. Ltd.
  18. 18.Key Experts

Loading the sample request form…